Internal Medicine, AMITA Health Saint Francis Hospital Evanston, Evanston, Illinois, USA.
Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
BMJ Case Rep. 2021 Feb 5;14(2):e239568. doi: 10.1136/bcr-2020-239568.
Iatrogenic iron overload, which is not uncommon in patients undergoing long-term haemodialysis, arises from a combination of multiple red cell transfusions and parenteral iron infusions that are administered to maintain a haemoglobin concentration of approximately 10 g/dL. Although iron overload due to genetic haemochromatosis is conventionally managed by phlebotomy, patients with haemoglobinopathies and chronic transfusion-induced iron overload are treated with iron-chelation therapy. However, the management of iron overload in our patient who presented with hepatic dysfunction and immunosuppressive drug-induced mild anaemia in the post-renal transplant setting posed unique challenges. We report on the decision-making process used in such a case that led to a successful clinical resolution of hepatic iron overload through the combined use of phlebotomy and erythropoiesis stimulating agents, while avoiding use of iron-chelating agents that could potentially compromise both hepatic and renal function.
医源性铁过载在长期接受血液透析的患者中并不少见,它是由多次红细胞输注和为维持血红蛋白浓度约 10g/dL 而给予的静脉铁输注共同引起的。尽管由于遗传性血色素沉着症引起的铁过载通常通过放血来治疗,但血红蛋白病和慢性输血引起的铁过载患者则采用铁螯合疗法进行治疗。然而,在肾移植后出现肝功能障碍和免疫抑制药物诱导的轻度贫血的患者中,铁过载的管理带来了独特的挑战。我们报告了在这种情况下使用的决策过程,该过程通过联合使用放血和促红细胞生成素成功地解决了肝铁过载,同时避免了使用可能损害肝肾功能的铁螯合剂。